Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort
HIV Medicine · 2025-11 · 26 (11) · 1707-1716
DOI: 10.1111/hiv.70105 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift HIV Medicine, online erschienen am 30.08.2025. Verfasst von Gerald Pierone und 7 weiteren Autor:innen. Beteiligte Einrichtung: Whole Family Health Center, Vero Beach, Florida, USA. Hauptthemen laut MEDLINE: HIV Infections, Heterocyclic Compounds, 3-Ring, Lamivudine, Emtricitabine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Objectives
To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed‐dose combination 3‐drug and 2‐drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US.
Methods
From the OPERA cohort, ART‐experienced, virologically suppressed (viral load
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Whole Family Health Center, Vero Beach, Florida, USA.
- Epividian, Raleigh, North Carolina, USA.
- CAN Community Health, Fort Lauderdale, Florida, USA.
- Gilead Sciences, Inc., Foster City, California, USA.
- Mount Sinai Health System, New York, New York, USA.
ORCID-Profile: Gerald Pierone, Laurence Brunet, Jennifer S Fusco, Megan S Dunbar
Förderung
- Gilead Sciences
Zitieren
APA
Pierone, G., Brunet, L., Fusco, J. S., Sension, M. G., Dunbar, M. S., Gruber, J., Dieterich, D. T., & Fusco, G. P. (2025). Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort. HIV Medicine, 26(11), 1707-1716. https://doi.org/10.1111/hiv.70105
Vancouver
Pierone G, Brunet L, Fusco JS, Sension MG, Dunbar MS, Gruber J, et al. Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort. HIV Medicine. 2025;26(11):1707-1716. doi:10.1111/hiv.70105
BibTeX
@article{Pierone2025,
author = {Pierone, Gerald and Brunet, Laurence and Fusco, Jennifer S and Sension, Michael G and Dunbar, Megan S and Gruber, Joshua and Dieterich, Douglas T and Fusco, Gregory P},
title = {Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort},
journal = {HIV Medicine},
year = {2025},
volume = {26},
number = {11},
pages = {1707--1716},
doi = {10.1111/hiv.70105}
}
EUVIMED